# HZSKBIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hzskbio

- Industry: Biotechnology
- Headquarters: Huzhou, China
- Website: www.shenkebio.com
- Latest round: Series B (Jan 19, 2023)
- Investors on record: 6

## About

Based in Huzhou, China, and established in 2012, HZSKBIO is a biotechnology company that provides testing technology services and testing regent kits for biological medical drugs. It has two R&D centres in Huzhou, and Shanghai. The Huzhou R&D centre has a protein, and nucleic acid testing lab, cell lab, and microbiology lab, which is equipped with fluorescence quantification PCR equipment, laser scanners, protein Purification, and other lab equipment. HZSKBIO undertook more than 30 result transform programs and 6 province-level technology programs and served more than 500 biopharmaceutical companies. It also established a production base and received quality management system certification, ISO13485. In 2016, it launched rHCD testing reagent kits. In 2018, it launched mycoplasma DNA extraction and detection reagent kits, and human residual DNA pieces analysis and detection reagent kits. In 2019, it launched CAR gene copy number detection reagent kits. In 2020, it launched reverse transcriptase activity assay kits and kanamycin residue assay kits.

HZSKBIO's products can be divided into pre-precess supported equipment systems, qPCR detection reagent kits, dPCR detection reagent kits, and ELISA detection reagent kits. The qPCR detection kits include host cell residual DNA and RNA detection reagent kits, virus detection reagent kits, reverse transcriptase activity detection reagent kits, and CAR copy number detection reagent kits. And the ELISA detection reagent kits include kanamycin residue detection reagent kits, host cell protein detection reagent kits, and nuclease residue detection reagent kits.

## Funding rounds

- Series B, Jan 19, 2023 — CLSA Capital Partners, CITIC Goldstone Fund Management, China International Capital Corporation, CITIC Securities, Riverhead Capital, Huzhou Industrial Investment Development Group Co.,Ltd.

## Investors

- CLSA Capital Partners (https://capitalatlas.ai/funds/clsa-capital-partners) — Series B
- CITIC Goldstone Fund Management (https://capitalatlas.ai/funds/citic-goldstone-fund-management) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- CITIC Securities — Series B
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series B
- Huzhou Industrial Investment Development Group Co.,Ltd. — Series B